Article

Daily Medication Pearl: Buprenorphine (Butrans)

Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

Medication Pearl of the Day: Buprenorphine (Butrans)

Indication: Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.

Insight:

  • Dosing: Doses of 7.5, 10, 15, and 20 mcg/hour are for opioid experienced patients only.
  • Dosage forms: Transdermal system 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.
  • Adverse events: Most common adverse reactions (≥ 5%) include nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
  • Mechanism of action: Buprenorphine is a partial agonist at mu opioid receptors.

Source: BUTRANS label (fda.gov)

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com